

# Luis A Pardo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7839252/publications.pdf>

Version: 2024-02-01

109  
papers

7,421  
citations

71102

41  
h-index

54911

84  
g-index

115  
all docs

115  
docs citations

115  
times ranked

6664  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Union of Pharmacology. LIII. Nomenclature and Molecular Relationships of Voltage-Gated Potassium Channels. <i>Pharmacological Reviews</i> , 2005, 57, 473-508.	16.0	785
2	Voltage-gated potassium channels as therapeutic targets. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 982-1001.	46.4	644
3	The roles of K <sup>+</sup> channels in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 39-48.	28.4	391
4	Oncogenic potential of EAG K <sup>+</sup> channels. <i>EMBO Journal</i> , 1999, 18, 5540-5547.	7.8	373
5	Potassium channels in cell cycle and cell proliferation. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130094.	4.0	305
6	Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. <i>Molecular Psychiatry</i> , 2014, 19, 1143-1149.	7.9	293
7	Voltage-Gated Potassium Channels in Cell Proliferation. <i>Physiology</i> , 2004, 19, 285-292.	3.1	251
8	Extracellular K <sup>+</sup> specifically modulates a rat brain K <sup>+</sup> channel.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 2466-2470.	7.1	229
9	Overexpression of Eag1 potassium channels in clinical tumours. <i>Molecular Cancer</i> , 2006, 5, 41.	19.2	227
10	Ether-Å-go-go encodes a voltage-gated channel permeable to K <sup>+</sup> and Ca <sup>2+</sup> and modulated by cAMP. <i>Nature</i> , 1993, 365, 445-448.	27.8	221
11	Monoclonal Antibody Blockade of the Human Eag1 Potassium Channel Function Exerts Antitumor Activity. <i>Cancer Research</i> , 2007, 67, 7343-7349.	0.9	196
12	Role of Voltage-gated Potassium Channels in Cancer. <i>Journal of Membrane Biology</i> , 2005, 205, 115-124.	2.1	178
13	Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors. <i>Journal of Biological Chemistry</i> , 2008, 283, 36234-36240.	3.4	149
14	Ether Å go-go Potassium Channels as Human Cervical Cancer Markers. <i>Cancer Research</i> , 2004, 64, 6996-7001.	0.9	143
15	C-terminal domains implicated in the functional surface expression of potassium channels. <i>EMBO Journal</i> , 2003, 22, 395-403.	7.8	122
16	Mechanism of Block of hEag1 K <sup>+</sup> Channels by Imipramine and Astemizole. <i>Journal of General Physiology</i> , 2004, 124, 301-317.	1.9	122
17	Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis. <i>Neurobiology of Disease</i> , 2008, 30, 162-173.	4.4	118
18	Silencing the Activity and Proliferative Properties of the Human Eag1 Potassium Channel by RNA Interference. <i>Journal of Biological Chemistry</i> , 2006, 281, 13030-13037.	3.4	104

#	ARTICLE	IF	CITATIONS
19	Cell Cycle-related Changes in the Conducting Properties of r-eag K+ Channels. <i>Journal of Cell Biology</i> , 1998, 143, 767-775.	5.2	101
20	The potassium channel Ether A go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. <i>Molecular Cancer</i> , 2010, 9, 18.	19.2	94
21	Ether A go-go potassium channel expression in soft tissue sarcoma patients. <i>Molecular Cancer</i> , 2006, 5, 42.	19.2	89
22	Ion channels: functional expression and therapeutic potential in cancer. <i>EMBO Reports</i> , 2008, 9, 512-515.	4.5	87
23	Eag1: An Emerging Oncological Target. <i>Cancer Research</i> , 2008, 68, 1611-1613.	0.9	78
24	Potassium channels as tumour markers. <i>FEBS Letters</i> , 2006, 580, 2850-2852.	2.8	77
25	Voltage-dependent gating of KCNH potassium channels lacking a covalent link between voltage-sensing and pore domains. <i>Nature Communications</i> , 2015, 6, 6672.	12.8	76
26	TRPM8 Ion Channels Differentially Modulate Proliferation and Cell Cycle Distribution of Normal and Cancer Prostate Cells. <i>PLoS ONE</i> , 2012, 7, e51825.	2.5	76
27	Kv10.1 K+ channel: from physiology to cancer. <i>Pflugers Archiv European Journal of Physiology</i> , 2016, 468, 751-762.	2.8	72
28	Mitosis-promoting factor-mediated suppression of a cloned delayed rectifier potassium channel expressed in <i>Xenopus</i> oocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 537-542.	7.1	69
29	A CAG repeat polymorphism of <i>KCNN3</i> predicts SK3 channel function and cognitive performance in schizophrenia. <i>EMBO Molecular Medicine</i> , 2011, 3, 309-319.	6.9	63
30	Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody. <i>Molecular Cancer</i> , 2011, 10, 109.	19.2	58
31	Functional KV10.1 Channels Localize to the Inner Nuclear Membrane. <i>PLoS ONE</i> , 2011, 6, e19257.	2.5	57
32	Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. <i>Neuroscience</i> , 2008, 155, 833-844.	2.3	56
33	Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice. <i>Human Molecular Genetics</i> , 2013, 22, 2247-2262.	2.9	56
34	Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival. <i>BMC Cancer</i> , 2015, 15, 839.	2.6	55
35	Alternating pH landscapes shape epithelial cancer initiation and progression: Focus on pancreatic cancer. <i>BioEssays</i> , 2017, 39, 1600253.	2.5	53
36	Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. <i>Pflugers Archiv European Journal of Physiology</i> , 2000, 441, 167-174.	2.8	49

#	ARTICLE	IF	CITATIONS
37	Glycosylation of Eag1 (Kv10.1) Potassium Channels. <i>Journal of Biological Chemistry</i> , 2005, 280, 29506-29512.	3.4	47
38	Cyclic expression of the voltage-gated potassium channel K <sub>V</sub> 10.1 promotes disassembly of the primary cilium. <i>EMBO Reports</i> , 2016, 17, 708-723.	4.5	47
39	Demonstration of an inwardly rectifying K <sup>+</sup> current component modulated by thyrotropin-releasing hormone and caffeine in GH 3 rat anterior pituitary cells. <i>Pflügers Archiv European Journal of Physiology</i> , 1997, 435, 119-129.	2.8	44
40	K <sub>V</sub> 10.1 opposes activity-dependent increase in Ca <sup>2+</sup> influx into the presynaptic terminal of the parallel fibre-Purkinje cell synapse. <i>Journal of Physiology</i> , 2015, 593, 181-196.	2.9	44
41	Frequent aberrant expression of the human ether A-go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications. <i>Journal of Molecular Medicine</i> , 2012, 90, 1173-1184.	3.9	43
42	Periodic expression of Kv10.1 driven by pRb/E2F1 contributes to G2/M progression of cancer and non-transformed cells. <i>Cell Cycle</i> , 2016, 15, 799-811.	2.6	43
43	Characterization of Eag1 Channel Lateral Mobility in Rat Hippocampal Cultures by Single-Particle-Tracking with Quantum Dots. <i>PLoS ONE</i> , 2010, 5, e8858.	2.5	42
44	Eag1 as a cancer target. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 837-843.	3.4	40
45	Kv10.1 potassium channel: from the brain to the tumors. <i>Biochemistry and Cell Biology</i> , 2017, 95, 531-536.	2.0	37
46	Gs Couples Thyrotropin-releasing Hormone Receptors Expressed in <i>Xenopus</i> Oocytes to Phospholipase C. <i>Journal of Biological Chemistry</i> , 1995, 270, 3554-3559.	3.4	35
47	APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1. <i>Marine Drugs</i> , 2017, 15, 287.	4.6	32
48	Eag1 potassium channels as markers of cervical dysplasia. <i>Oncology Reports</i> , 2011, 26, 1377-83.	2.6	31
49	CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. <i>PLoS ONE</i> , 2015, 10, e0130519.	2.5	31
50	A new mechanism of voltage-dependent gating exposed by KV10.1 channels interrupted between voltage sensor and pore. <i>Journal of General Physiology</i> , 2017, 149, 577-593.	1.9	30
51	Molecular basis for different pore properties of potassium channels from the rat brain Kv1 gene family. <i>Pflügers Archiv European Journal of Physiology</i> , 1997, 434, 661-668.	2.8	29
52	Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin. <i>European Biophysics Journal</i> , 2016, 45, 709-719.	2.2	29
53	New Structures and Gating of Voltage-Dependent Potassium (Kv) Channels and Their Relatives: A Multi-Domain and Dynamic Question. <i>International Journal of Molecular Sciences</i> , 2019, 20, 248.	4.1	28
54	Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy. <i>Current Medicinal Chemistry</i> , 2012, 19, 675-682.	2.4	26

#	ARTICLE	IF	CITATIONS
55	Cortactin Controls Surface Expression of the Voltage-gated Potassium Channel KV10.1. <i>Journal of Biological Chemistry</i> , 2012, 287, 44151-44163.	3.4	26
56	Rapid Internalization of the Oncogenic K <sup>+</sup> Channel KV10.1. <i>PLoS ONE</i> , 2011, 6, e26329.	2.5	25
57	Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide. <i>FEBS Letters</i> , 2006, 580, 5059-5066.	2.8	24
58	The EAG Voltage-Dependent K <sup>+</sup> Channel Subfamily: Similarities and Differences in Structural Organization and Gating. <i>Frontiers in Pharmacology</i> , 2020, 11, 411.	3.5	24
59	SK3 Channel Overexpression in Mice Causes Hippocampal Shrinkage Associated with Cognitive Impairments. <i>Molecular Neurobiology</i> , 2017, 54, 1078-1091.	4.0	23
60	Discovery of K <sup>v</sup> 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges. <i>Medicinal Research Reviews</i> , 2021, 41, 2423-2473.	10.5	23
61	Human Glioma-Initiating Cells Show a Distinct Immature Phenotype Resembling but Not Identical to NG2 Glia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 307-324.	1.7	21
62	Re-Expression of a Developmentally Restricted Potassium Channel in Autoimmune Demyelination. <i>American Journal of Pathology</i> , 2007, 171, 589-598.	3.8	20
63	Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment. <i>Medicinal Research Reviews</i> , 2022, 42, 183-226.	10.5	19
64	Caffeine enhancement of electrical activity through direct blockade of inward rectifying K <sup>+</sup> currents in GH3 rat anterior pituitary cells. <i>Pflugers Archiv European Journal of Physiology</i> , 1996, 431, 443-451.	2.8	18
65	Ether-Å-go-go 1 (Eag1) Potassium Channel Expression in Dopaminergic Neurons of Basal Ganglia is Modulated by 6-Hydroxydopamine Lesion. <i>Neurotoxicity Research</i> , 2012, 21, 317-333.	2.7	18
66	KV10.1 K <sup>+</sup> -channel plasma membrane discrete domain partitioning and its functional correlation in neurons. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014, 1838, 921-931.	2.6	18
67	Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil. <i>Journal of Cellular Physiology</i> , 2017, 232, 2019-2032.	4.1	18
68	Physical and functional interaction of K <sup>v</sup> 10.1 with Rabaptin-5 impacts ion channel trafficking. <i>FEBS Letters</i> , 2012, 586, 3077-3084.	2.8	17
69	Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1. <i>PLoS ONE</i> , 2017, 12, e0188811.	2.5	17
70	Activation of adenylate cyclase incdc25mutants of <i>Saccharomyces cerevisiae</i> . <i>FEBS Letters</i> , 1993, 319, 237-243.	2.8	16
71	In vivo imaging of tumour xenografts with an antibody targeting the potassium channel Kv10.1. <i>European Biophysics Journal</i> , 2016, 45, 721-733.	2.2	16
72	A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 686.	3.5	16

#	ARTICLE	IF	CITATIONS
73	Inhibition of Kv10.1 Channels Sensitizes Mitochondria of Cancer Cells to Antimetabolic Agents. <i>Cancers</i> , 2020, 12, 920.	3.7	16
74	Alternatively Spliced Isoforms of KV10.1 Potassium Channels Modulate Channel Properties and Can Activate Cyclin-dependent Kinase in <i>Xenopus</i> Oocytes. <i>Journal of Biological Chemistry</i> , 2015, 290, 30351-30365.	3.4	15
75	The electric fence to cell cycle progression: Do local changes in membrane potential facilitate disassembly of the primary cilium?. <i>BioEssays</i> , 2017, 39, 1600190.	2.5	15
76	The Interplay between Dysregulated Ion Transport and Mitochondrial Architecture as a Dangerous Liaison in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5209.	4.1	15
77	Nucleofection induces non-specific changes in the metabolic activity of transfected cells. <i>Molecular Biology Reports</i> , 2012, 39, 2187-2194.	2.3	14
78	K <sup>+</sup> channels as therapeutic targets in oncology. <i>Future Medicinal Chemistry</i> , 2010, 2, 745-755.	2.3	13
79	The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model. <i>Investigational New Drugs</i> , 2019, 37, 1044-1051.	2.6	13
80	Kv10.1 Regulates Microtubule Dynamics during Mitosis. <i>Cancers</i> , 2020, 12, 2409.	3.7	13
81	Production of levan from <i>Bacillus subtilis</i> var. natto and apoptotic effect on SH-SY5Y neuroblastoma cells. <i>Carbohydrate Polymers</i> , 2021, 273, 118613.	10.2	12
82	<i>Eag 1</i> , <i>Eag 2</i> and <i>Kcnn3</i> gene brain expression of isolated reared rats. <i>Genes, Brain and Behavior</i> , 2010, 9, 918-924.	2.2	11
83	<i>Eag1</i> , <i>Eag2</i> , and <i>SK3</i> potassium channel expression in the rat hippocampus after global transient brain ischemia. <i>Journal of Neuroscience Research</i> , 2012, 90, 632-640.	2.9	10
84	Voltage-gated potassium channels (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	10
85	RNA interference with <i>EAG1</i> enhances interferon gamma injury to glioma cells in vitro. <i>Anticancer Research</i> , 2013, 33, 865-70.	1.1	10
86	Concept of a selective tumour therapy and its evaluation by near-infrared fluorescence imaging and flat-panel volume computed tomography in mice. <i>European Journal of Radiology</i> , 2009, 70, 286-293.	2.6	9
87	PIST (GOPC) modulates the oncogenic voltage-gated potassium channel KV10.1. <i>Frontiers in Physiology</i> , 2013, 4, 201.	2.8	9
88	Comparative analysis of alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism <i>ATP1A3</i> mutations reveals functional deficits, which do not correlate with disease severity. <i>Neurobiology of Disease</i> , 2020, 143, 105012.	4.4	8
89	In vitro activation of the <i>Saccharomyces cerevisiae</i> Ras/adenylate cyclase system by glucose and some of its analogues. <i>FEBS Letters</i> , 1991, 290, 43-48.	2.8	7
90	The voltage dependence of hEag currents is not determined solely by membrane-spanning domains. <i>European Biophysics Journal</i> , 2009, 38, 279-284.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Antibodies Targeting K <sub>v</sub> Potassium Channels: A Promising Treatment for Cancer. <i>Bioelectricity</i> , 2019, 1, 180-187.	1.1	7
92	3D Pharmacophore-Based Discovery of Novel KV10.1 Inhibitors with Antiproliferative Activity. <i>Cancers</i> , 2021, 13, 1244.	3.7	6
93	Design of New Potent and Selective Thiophene-Based KV1.3 Inhibitors and Their Potential for Anticancer Activity. <i>Cancers</i> , 2022, 14, 2595.	3.7	5
94	Altered Ligand Dissociation Rates in Thyrotropin-Releasing Hormone Receptors Mutated in Glutamine 105 of Transmembrane Helix III. <i>Biochemistry</i> , 1997, 36, 3308-3318.	2.5	4
95	Hippocampal ether-Å-go-go1 potassium channels blockade: Effects in the startle reflex and prepulse inhibition. <i>Neuroscience Letters</i> , 2014, 559, 13-17.	2.1	4
96	Molecular Dynamics-Derived Pharmacophore Model Explaining the Nonselective Aspect of KV10.1 Pore Blockers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8999.	4.1	3
97	Voltage-gated potassium channels (K <sub>v</sub> ) in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	3
98	Voltage-Gated Potassium Channels Beyond the Action Potential. <i>Bioelectricity</i> , 2022, 4, 117-125.	1.1	3
99	Effect of glucose analogues on yeast adenylate cyclase <i>in vitro</i> . <i>Biochemical Society Transactions</i> , 1989, 17, 1010-1011.	3.4	1
100	Glucose activation of adenylate cyclase in <i>Saccharomyces cerevisiae</i> mutants lacking glucose-phosphorylating enzymes. <i>Cellular Signalling</i> , 1993, 5, 435-441.	3.6	1
101	Measurement of Microtubule Dynamics by Spinning Disk Microscopy in Monopolar Mitotic Spindles. <i>Journal of Visualized Experiments</i> , 2019, . .	0.3	1
102	miR449 Protects Airway Regeneration by Controlling AURKA/HDAC6-Mediated Ciliary Disassembly. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7749.	4.1	1
103	801 Frequent Aberrant Expression of the Human Ether a Go-go (hEAG1) Potassium Channel in Head and Neck Cancer – Pathobiological Mechanisms and Clinical Implications. <i>European Journal of Cancer</i> , 2012, 48, S191.	2.8	0
104	Association of Kv10.1 to Different Plasma Membrane Domains and its Interaction with other Membrane Associated Proteins in Endogenous Expression Systems. <i>Biophysical Journal</i> , 2012, 102, 680a.	0.5	0
105	MyD88 signaling mediates the effects of the innate immune response in cerebellar short-term synaptic plasticity. <i>Journal of Neuroimmunology</i> , 2014, 275, 95.	2.3	0
106	Discontinuity between the Voltage-Sensor and the Pore Domain does not Abolish Voltage-Gating of Kv10.1 Potassium Channel. <i>Biophysical Journal</i> , 2015, 108, 427a.	0.5	0
107	Probing the Gating of Kv10.1 Channels by MTS Reagents. <i>Biophysical Journal</i> , 2017, 112, 248a.	0.5	0
108	Antitumor efficacy of obtustatin in S-180 sarcoma mouse model. <i>Toxicol</i> , 2019, 159, S19.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Chronic Acidosis Rewires Cancer Cell Metabolism Through PPAR $\alpha$ Signaling. SSRN Electronic Journal, 0, , .	0.4	0